FDA approves Merck vaccine to treat shingles

Share this article:
The FDA on Friday granted approval to Merck's Zostavax vaccine to treat patients over age 60 with the often-painful disease shingles.
"This vaccine gives healthcare providers an important tool that can help prevent an illness that affects many older Americans and often results in significant chronic pain," said Jesse Goodman, director of the FDA's Center for Biologics Evaluation and Research in a release.
Zostavax was studied in approximately 38,000 individuals throughout the US who were 60 years of age and older. Of these 38,000 people, half received Zostavax and half received a placebo. All study participants were then followed for an average of three years to see if they developed shingles and, if they did, how long the pain lasted.
At the conclusion of the study, researchers found that, overall, in those ages 60 and above the vaccine reduced the occurrence of shingles by about 50%. For individuals ages 60-69 it reduced occurrence by 64%.
Zostavax is priced at $152.50 for a single dose and Merck expects to begin shipping the vaccine soon.
However, analysts believe Zostavax sales will give only a minimal boost to a beleaguered Merck, with a predicted sales peak of $300 million annually by 2010.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Genentech shift could prove costly for hospitals

Genentech will use specialty distributors rather than wholesalers, hospitals pharmacy directors have learned.

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies